Moleculin Biotech, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a quarterly filing. The filing was signed March 22, 2024; financial statements reflect the subsequent 1-for-15 reverse stock split.
Business context
Moleculin is a clinical-stage pharmaceutical company with no approved products or product-sales revenue. Its lead program, Annamycin, is being developed for relapsed or refractory acute myeloid leukemia (AML) and soft-tissue sarcoma lung metastases. Other programs include the WP1066 portfolio, focused on immune/transcription modulation, and WP1122, focused on glycolysis inhibition. Most assets and research are licensed from MD Anderson. The company relies on contract manufacturers and has no sales organization.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $19.5 million | $19.0 million |
| General and administrative expense | $10.0 million | $11.5 million |
| Total operating expenses | $29.6 million | $30.6 million |
| Net loss | $29.8 million | $29.0 million |
| Net cash used in operations | $24.1 million | $27.6 million |
- R&D expense increased about $0.5 million, primarily reflecting a $1.5 million WPD sublicense termination payment, partly offset by timing-related reductions in trial and sponsored-research costs. G&A fell about $1.5 million, mainly due to lower regulatory, legal, consulting and advisory costs.
- Net loss increased about $0.7 million. The comparison included a $1.0 million noncash warrant fair-value loss in 2023 versus a $1.3 million gain in 2022; higher interest income partly offset the loss.
- At year-end, cash and cash equivalents were $23.6 million; current assets were $26.3 million and current liabilities $6.8 million. Stockholders’ equity was $26.1 million, down from $52.2 million.
- Operating cash burn declined year over year. Financing activities provided $4.7 million in 2023, principally from a December stock-and-warrant offering; there were no comparable net financing proceeds in 2022.
- Total liabilities were $12.1 million, including a $4.9 million warrant liability and lease liabilities. The balance sheet reports no conventional borrowings. The warrant liability rose from $0.1 million in 2022, and its remeasurement contributed to earnings volatility.
- No meaningful gross margin is available because the company reported no revenue. The filing reports no dividends and no share repurchases in 2023.
Material changes and developments
- Cash declined from $43.1 million to $23.6 million during 2023. The company’s accumulated deficit reached $131.6 million.
- The December 2023 financing generated $4.5 million gross proceeds and included common shares, pre-funded warrants and warrants exercisable at $9.60 per share, subject to stated terms. The company also issued shares under its Lincoln Park equity line.
- The company terminated its WPD sublicense in March 2023, paying $0.7 million cash and issuing $0.8 million of stock, and reacquired rights in certain territories.
- On March 22, 2024, after year-end, the company completed a 1-for-15 reverse stock split. It reported 2,227,516 common shares outstanding as of March 14, 2024, before giving effect to subsequent share activity described in the filing.
Outlook, clinical commentary and risks
- Management’s MD&A says year-end cash was expected to fund planned operations into the fourth quarter of 2024 without additional equity for cash. However, the audited financial-statement note says cash was not sufficient to fund planned operations for at least one year from issuance and identifies substantial doubt about the company’s ability to continue as a going concern. The auditor’s report also highlights this substantial doubt. Additional financing, partnerships, licensing, spending delays or reductions may be needed; none is assured.
- Management described a potential Annamycin-plus-cytarabine Phase 2b/3 AML program as a future objective, with a possible start in late 2024 or early 2025, subject to regulatory discussions, financing and development progress. The company planned an FDA end-of-Phase-2 meeting using second-line MB-106 data.
- MB-106 reported preliminary response data: a 39% composite complete response rate among 18 evaluable subjects overall and 60% among 10 second-line subjects. The company cautions that these results are preliminary, small-sample and subject to change; durability is still developing.
- MB-107’s U.S. STS lung-metastasis trial completed enrollment and treatment; follow-up continued. Reported response and survival data are preliminary. The externally funded Polish investigator-led trial remained in dose escalation, with a dose-limiting toxicity noted.
- The company reported no cardiotoxicity in Annamycin subjects reviewed by its independent expert to date, but the review was incomplete and clinical data remain preliminary. This does not establish future safety or efficacy.
- Principal risks include the need for additional capital and the going-concern uncertainty; failure or delay in clinical trials or regulatory approval; preliminary, uncontrolled clinical results; limited manufacturing sources, including a single API source for Annamycin; dependence on MD Anderson licenses and external collaborators; competition; dilution from securities; and possible Nasdaq listing issues.
- The SEC has an ongoing investigation following a March 2022 subpoena concerning individuals and entities and the development and statements about the company’s COVID-19 drug candidate. The company says it cannot predict the outcome and has incurred related legal expenses of approximately $1.5 million in 2023. The filing states the investigation is not a finding of wrongdoing.
- The company reported effective management disclosure controls and internal control over financial reporting as of year-end. The auditor issued an unqualified opinion on the financial statements and reported no critical audit matters; it did not opine on internal-control effectiveness.
Most important facts for investors to verify
- Reconcile the contrasting runway statements in MD&A and the audited going-concern note, and assess cash needs against trial plans and subsequent financing.
- Review the full financial statements and warrant terms, including potential dilution, warrant-liability valuation and the effect of the reverse split.
- Track final, independently reviewable MB-106 and MB-107 results, including response definitions, durability, safety and regulatory feedback; distinguish them from preliminary company-reported data.
- Check the status and timing of any FDA end-of-Phase-2 meeting, pivotal-trial plan, financing or partnering arrangements, and whether proposed trial costs are funded.
- Monitor the SEC investigation, related legal costs and insurance claim; the filing reports no approved reimbursement amount.
- Confirm Nasdaq bid-price compliance following the reverse split and review the company’s updated share count and remaining equity financing capacity.